Published: November 2023
On 01 November 2023, Aldeyra Therapeutics entered into licensing and commercialization agreement with AbbVie. Under the collaboration, AbbVie acquired a an exclusive license to co-develop, manufacture, and commercialize reproxalap for the treatment of patients suffering from dry eye disease.
Additionally, Aldeyra has received a non-refundable option fee of $1 million and an upfront payment of $100 million less option fees if AbbVie chooses to exercise the option. Further, Aldeyra is eligible to receive up to $300 million in regulatory and commercial milestone payments, inclusive of a $100 million milestone payment after FDA approval of reproxalap in dry eye disease.
According to Roots Analysis, the Dry Eye Diseases Market is anticipated to grow at a stable rate during the forecast period.
For detailed insights about this domain, check out our report on Dry Eye Diseases Market or email email@example.com
You may also be interested in the following titles:
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES